Lyell Immunopharma

Lyell Immunopharma, Inc.
TypePublic
Nasdaq: LYEL
IndustryBiotechnology
Pharmaceuticals
Founded2018
HeadquartersSan Francisco, California, U.S.
Websitelyell.com

Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell (chimeric antigen receptor therapies), using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors.

Lyell Immunopharma, Inc. Logo.